Recorded Presentation from the NCCN Pharmacy Updates: Novel Therapies for Treating ESR1 and RET-Fusion Mutations in Breast Cancer

Treatment options for later line hormone receptor positive/HER2-negative locally advanced or metastatic breast cancer are an unmet need. It is important for clinicians to have an understanding of the current treatment approaches, especially for disease that has progressed and also demonstrated mutations such as ESR1 and RET-fusion. As targeted therapy and precision medicine continue to be brought to the forefront of many malignancies, clinicians must be equipped to manage toxicities and provide appropriate supportive care recommendations during a treatment course.

Target Audience

This program is designed to meet the educational needs of pharmacists, physicians, nurses, nurse practitioners, physician associates/assistants, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Describe the prevalence of ESR1 and RET-fusion mutations in locally advanced and metastatic breast cancer.
  • Illustrate the role of targeted agents for ESR1 and RET-fusion mutations in the setting of locally advanced or metastatic breast cancer.
  • Discuss key patient counseling and monitoring considerations for the use of elacestrant and selpercatinib in locally advanced or metastatic breast cancer.
Additional information
Supporters: 

This activity is supported by educational grants from GSK and Menarini-Stemline. This educational activity is supported by a medical education grant from Exelixis, Inc. This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA. This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
    • 1.00 ANCC Pharmacology Contact Hours
  • 1.00 Participation
Course opens: 
11/01/2024
Course expires: 
11/01/2025
Cost:
$0.00

Amy Ly Indorf, PharmD, BCOP
Fred Hutchinson Cancer Center

 

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below has no relevant financial relationships with ineligible companies to disclose.

Amy Ly Indorf, PharmD, BCOP

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour. This activity offers 1.0 pharmacotherapeutic contact hour for nurses.

Pharmacists
NCCN designates this application-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-24-115-H01-P

Physician Associates/Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until November 1, 2025. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
    • 1.00 ANCC Pharmacology Contact Hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing